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Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE) 
exonuclease domain define the important subtype of ultramutated tumours (“POLE-
ultramutated”) within the novel molecular classification of endometrial carcinoma (EC). 
However, clinical implementation of this classifier requires systematic evaluation of the 
pathogenicity of POLE mutations.  To address this, we examined base changes, 
tumour mutational burden (TMB), DNA microsatellite instability (MSI) status, POLE 
variant frequency and the results from six in silico tools on 82 EC with whole-exome 
sequencing from The Cancer Genome Atlas (TCGA).  Of these, 41 had one of five 
known pathogenic POLE exonuclease domain mutations (EDM) and showed 
characteristic genomic alterations: C>A substitution >20%, T>G substitutions >4%, 
C>G substitutions < 0.6%, indels < 5%, TMB > 100mut/Mb. A scoring system to assess 
these alterations (POLE-score) was developed; based on their scores 7/18 (39%) 
additional tumours with EDM were classified as POLE-ultramutated EC, and the 6 
POLE mutations present in these tumours were considered pathogenic. Only 1/23 (4%) 
tumours with non-EDM showed these genomic alterations, indicating that a large 
majority of mutations outside the exonuclease domain are not pathogenic. The 
infrequent combination of MSI-H with POLE EDM led us to investigate the clinical 
significance of this association. Tumours with pathogenic POLE EDM co-existent with 
MSI-H showed genomic alterations characteristic of POLE-ultramutated EC. In a 
pooled analysis of 3,361 EC, 13 EC with DNA mismatch repair deficiency(MMRd)/MSI-
H and a pathogenic POLE EDM had a 5-year recurrence-free survival (RFS) of 92.3%, 
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comparable to previously reported POLE-ultramutated EC. Additionally, 14 cases with 
non-pathogenic POLE EDM and MMRd/MSI-H had 5-year RFS of 76.2%, similar to 
MMRd/MSI-H, POLE wild-type EC, suggesting these should be categorised as MMRd, 
rather than POLE-ultramutated EC for prognostication. This work provides guidance on 
classification of EC with POLE mutations, facilitating implementation of POLE testing in 
routine clinical care. 
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Pathogenic somatic mutations in the exonuclease domain of the replicative DNA 
polymerase Pol epsilon (POLE) define a subgroup of endometrial cancers (EC) with 
ultramutation (frequently ≥100 mutations/Mb), characteristic mutation signature 
(COSMIC signature 10) [1], enhanced immune response [2, 3] and excellent clinical 
outcome [4–7].  “POLE ultramutated” EC (POLEmut EC) has therefore been proposed 
as a distinct clinical entity that can be diagnosed in the presence of a pathogenic POLE 
exonuclease domain mutation (EDM) [8]. For the five most common POLE mutations 
(P286R, V411L, S297F, A456P, and S459F) pathogenicity (in this sense meaning 
causal for tumour ultramutation) has been confirmed [4–6, 9–25], however, the 
classification of other, less frequent, POLE variants is currently challenging. This is 
becoming an urgent problem, as POLE sequencing for molecular EC classification is 
rapidly entering clinical practice.  
 
Previous work has shown that EC with a pathogenic POLE EDM typically display 
characteristic genomic alterations, with high prevalence of C>A substitutions, frequently 
exceeding 20%, low proportion of small insertion and deletion mutations (indels) and 
extremely high tumour mutational burden (TMB, >100 mut/Mb) [12,26]. In the pivotal 
2013 EC study from The Cancer Genome Atlas (TCGA), all 17 tumours classified as 
ultramutated had a POLE EDM, including recurrent P286R and V411L substitutions (8 
and 5 cases respectively), and one case each of S297F, A456P, M444K, and L424I 
substitutions [7]. Interestingly, 10 of 231 non-ultramutated EC in this study also had a 
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POLE mutation either within or outside the exonuclease domain. Following the TCGA 
report, further studies have confirmed the prevalence of the five pathogenic mutations 
listed above and identified additional variants of uncertain pathogenicity. The 
parameters by which to evaluate the latter are ill-defined, and thus classification of such 
cases is challenging, particularly in the absence of whole exome or whole genome 
sequencing (WES/WGS). In order to facilitate the classification of EC in clinical 
practice, we aimed to develop a scoring system to estimate pathogenicity of novel 
POLE mutations based on the presence or absence of genomic alterations associated 
with known pathogenic POLE mutations. We also sought to provide pragmatic 
guidelines for the interpretation of POLE variants in cases analysed by targeted POLE 
sequencing where such comprehensive genomic data are unavailable, being mindful 
that the designation of a tumour as POLE-ultramutated EC may lead to withholding 
treatment, given the very favourable prognosis of this EC molecular subtype, so that a 
conservative approach to diagnosis is warranted.  
 
Materials and methods 
Data extraction TCGA EC Cohort 
To analyse the base change proportions of the TCGA cohort of EC (n=530), we 
downloaded the MAF files (using Mutect for point somatic mutation call as well as small 
insertions and deletions (indels)), from Genome Data Commons 
(https://portal.gdc.cancer.gov/, accessed February 27th 2019). We used somatic called 
coding variants (single nucleotide substitutions (SNV), including synonymous 
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mutations, and indels) as mutation count. To estimate tumour mutational burden (TMB) 
we used 38 Mb as the estimate of the exome size. Microsatellite status, as defined by 
the Bethesda Protocol classification [27], was obtained from Genome Data Analysis 
Center (GDAC) database (https://gdac.broadinstitute.org/, accessed 30th October 
2018).  
COSMIC signatures from all 530 TCGA EC were obtained from mSignatureDB 
(http://tardis.cgu.edu.tw/msignaturedb/, accessed 22nd October 2019) [28,29]. 
 
Recurrence of somatic POLE mutations in EC and pancancer 
We searched for each somatic POLE mutation in the complete TCGA (Genome Data 
Commons) catalogues and COSMIC (https://cancer.sanger.ac.uk/cosmic, accessed 
10th January 2019), annotating their recurrence on all cancer types (pancancer) and 
exclusively within EC (supplementary material, Table S1). Recurrent mutations were 
defined as those present in two or more cancer samples in COSMIC and TCGA 
databases combined (cases present in both databases were counted only once). A 
mutation was considered non-recurrent if it was found only once.  
 
In silico prediction tools 
To evaluate the functional status of somatic POLE mutations, we used six widely-used 
in silico tools: SIFT [30], PROVEAN [31], PolyPhen-2 [32], PANTHER [33], SNAP2 [34] 
and the meta predictor REVEL [35]. SIFT is a multi-step algorithm using sequence-
based predictive features to predict the effect of single-nucleotide polymorphisms 
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(SNPs) [30]. PROVEAN extends this approach, additionally incorporating analysis of in-
frame insertions, deletions, and multiple substitutions [31]. PolyPhen-2 implements 
sequence-based and structure-based predictive features and compares wild-type and 
mutant allele through a decision tree [32]; “possibly damaging” results were interpreted 
as benign. PANTHER is based on protein sequence, using a metric based on 
evolutionary conservation on direct ancestors of the organism[33]; “possibly damaging” 
and “probably benign” results were interpreted as benign. SNAP2 is a neural network-
based classifier that uses sequence and structural-based data as inputs [34]. REVEL is 
an ensemble method based on 13 individual tools [35]; scores below 0.5 were 
considered benign.  
 
Somatic POLE mutations reported in EC and not detected in TCGA cases 
A review of the literature was undertaken, to the end of 2018, to identify EC in which 
POLE had been sequenced and the mutations published[6,7,9–15,17–22,24,25].  All 
literature contributing entries into the COSMIC database (POLE + endometrium) were 
reviewed; in addition, searches in PubMed and Web of Science were undertaken with 
keywords: ‘POLE + Endometrial + Carcinoma’ and ‘POLE + Endometrial + Cancer’ 
noting that ‘POLƐ’ is interpreted as ‘POLE' in these resources. 
 
DNA mismatch repair deficient/microsatellite unstable, POLE exonuclease 
domain mutated endometrial cancer cohort 
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Tumours with concomitant mismatch repair deficiency (MMRd) and somatic POLE 
EDM, and clinical follow-up were identified from a pooled cohort of 2,988 molecularly 
profiled EC across ten participating institutes (detailed description can be found in 
León-Castillo, et al [36]). Informed consent and ethical approvals were obtained 
according to local protocols in each participating centre. These tumours were combined 
with five tumours with concomitant microsatellite instability and POLE EDM from the 
2013 TCGA EC cohort [7] for survival analysis.  
 
Statistical analysis 
Nominal variables were compared by  χ2 statistics or Fisher’s exact test and ordinal 
variables using the Mann–Whitney test. All statistical tests were two-sided and 
statistical significance was accepted at p < 0.05. We generated Kaplan–Meier curves 
for Recurrence-Free Survival (RFS) and Overall Survival (OS) and differences were 
tested by the log-rank test. The median follow-up was estimated by the reverse 
Kaplan–Meier method. 
  




Genomic characteristics of endometrial cancers with somatic POLE mutations in 
the complete TCGA cohort 
To elucidate which genomic alterations best define pathogenic somatic POLE 
mutations (which we use in this context to mean very likely causal for tumour 
ultramutation), we used data from 530 EC profiled by TCGA, including those reported 
in the 2013 publication [7]. This included 82 tumours with a somatic POLE mutation, of 
which 59 (72%) were located within the exonuclease domain and 23 (28%) outside the 
exonuclease domain. The 59 exonuclease domain mutations comprised 21 unique 
variants; the five most common of which (P286R, 21 cases; V411L, 13 cases; S297F, 3 
cases; A456P, 2 cases; and S459F, 2 cases) were classified as pathogenic based on 
previous reports [7,8,26] and designated as “hotspot” POLE mutations for the purpose 
of this study (Table1).  
 
The location of each POLE mutation (exonuclease domain vs. non-exonuclease 
domain), its recurrent or non-recurrent status in endometrial and pan-cancer and pan-
cancer in the TCGA and COSMIC databases, and genomic characteristics are shown 
for all cases in Figure 1. As previously reported [1,7,12,26], the five hotspot POLE 
mutations were reliably associated with elevated tumour mutation burden (TMB) 
(median=268 Mut/Mb), which exceeded 100 mut/Mb (typically used to define 
ultramutation) in most tumours (33/41). Interestingly, TMB varied between different 
hotspot mutations (range 37.5 to 791.9 mut/Mb), and among tumours with identical 
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hotspot mutations (eg P286R: 41.9 to 550.1 mut/Mb). POLE hotspot-mutant EC 
typically displayed a high proportion of C>A substitutions (median 32.5%, >20% in 
37/41 tumours) and T>G substitutions (median 12.8%), whereas the proportion of C>G 
substitutions (median 0.3%), and indels (median 0.5%) was small. For comparison, 321 
microsatellite stable (MSS), POLE wild-type EC all had TMB <100 mut/Mb (median 
2.1), lower C>A proportion (median 13.5%) and  T>G proportion (median 3.9%), and 
higher C>G proportion (median 8.9%) and indel proportion (median 7.4%) (Table 2). 
We defined tumours with POLE hotspot mutations as a set of “true positives”, for 
subsequent identification of genomic alterations associated with pathogenic POLE 
mutations (Table 2). 
 
 Of the 41 TCGA EC with a somatic non-hotspot POLE mutation, 18 were located 
within the exonuclease domain. Comparing these to the 23 tumours with non-
exonuclease domain mutations, non-hotspot POLE exonuclease domain-mutant EC 
had a higher TMB (median 164.4 versus 42.8mut/Mb) and C>A proportion (median 
20.2% versus 10.8%), and lower C>G proportion (median 0.5% versus 1.0%) and indel 
proportion (median 5.2% versus 9.5%) (Table 2).  
 
MSI status was available for all TCGA EC, of which 35/82 cases with somatic 
POLE mutations (42.7%) were MSI-H. Comparison between EC with hotspot mutations 
and non-hotspot mutations within and outside the exonuclease domain revealed 
striking differences: only 4/41 (9.8%) of the TCGA EC with one of the 5 hotspot 
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mutations were MSI-H, whereas 14/18 (78%) EC with a non-hotspot exonuclease 
domain mutation and 17/23 (74%) EC with a non-exonuclease domain mutation were 
MSI-H (p<0.0001)). Analysis of the genomic architecture of these tumours revealed 
notable differences between groups. Tumours with hotspot POLE mutations and MSI 
had a high TMB (median TMB of 339.0 mut/Mb, >100mut/Mb in all 4 cases), high 
proportion of C>A and T>G substitutions (median 20.0% and 5.1% respectively), with 
low proportion of C>G substitutions (median 0.3%) and indels (median 2.8%) (Table 2). 
Tumours with non-hotspot POLE EDM and MSI had lower TMB (median 207.1 mut/Mb, 
>100mut/Mb in 9/14 cases), C>A and T>G proportions (median 10.8% and 1.6% 
respectively), similar proportion of C>G substitutions (median 0.5%) and higher indel 
proportion (median 6.7%) (Table 2). These differences were greater in tumours with a 
POLE mutation outside the exonuclease domain and concomitant MSI, which had 
median TMB of 48.5 mut/Mb (>100mut/Mb in 6/17 cases), C>A and T>G proportions 
9.9% and 1.6% respectively, C>G frequency of 0.9% and median indel proportion of 
14.5%. For comparison, of 127 MSI-H EC without a POLE mutation (MSI-H EC), only 
one case had a TMB above 100 mut/MB (median 21.5) or C>A proportion above 20% 
(median 9.1%); these cancers also had low T>G proportions (median 1.4%), higher 
C>G proportion (median 1.5%,) and high indel proportion (median 24.8%)  (Table 2). 
Thus, the genomic characteristics of MSI-H endometrial cancers with a POLE mutation 
outside the exonuclease domain are similar to those of MSI-H tumours without a POLE 
mutation. Consequently, the frequency with which MSI co-exists with POLE mutation 
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varies by POLE mutation location and is reflected in differing genomic architecture – 
consistent with variable pathogenicity of POLE mutations. 
 
These analyses confirm that EC with one of the five somatic hotspot POLE EDM 
carry characteristic genomic sequence alterations distinct from MSI-H and MSS, POLE-
wild-type EC. These genomic alterations are variably present in cases with non-hotspot 
POLE EDM and are uncommon in ECs with POLE mutations outside the exonuclease 
domain. The variation in the genomic correlates of POLE mutations by their location is 
mirrored by variation in the prevalence of MSI in cancers carrying these mutations, and 
in differences in the genomic architecture of tumours harbouring both defects. 
Collectively, these data confirm that different POLE mutations vary in pathogenicity and 
underscore the need for its reliable estimation to ensure accurate patient classification.  
 
Establishing a pathogenicity score for somatic POLE mutations 
Motivated by our preliminary analyses, we next used the TCGA WES data to develop a 
scoring system to assess pathogenicity of POLE mutations (defined as the likelihood 
they are associated with the characteristic ultramutated phenotype), using the hotspot 
POLE mutations as a truth set. Taking TMB and C>A, T>G, C>G and indel proportions 
as the most discriminating genomic alterations for these pathogenic mutations, and 
building on previous work [26], we developed a pragmatic scoring system in which 
tumours scored one point for each of the following: TMB>100 mut/Mb; C>A ≥20%; T>G 
≥4%; C>G ≤0.6%; and indels ≤5%. All 41 TCGA EC with a hotspot POLE mutation 
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scored 3–5 points, while 13/41 (31.7%) EC with a non-hotspot POLE mutation scored 
≥3 points, including 8/18 with exonuclease domain mutations, while 19/23 tumours with 
POLE mutations outside the exonuclease domain had scores ≤ 2, the exceptions being 
three tumours with score 3 (each of which had likely pathogenic mutations in POLD1: 
D316G, S478N, and L606M) and one scoring 5 points with a POLE R705W mutation. 
We therefore chose to focus on mutations in the exonuclease domain, given the 
infrequent association of non-exonuclease domain mutations with genomic alterations 
associated with ultramutated phenotype. 
 
To further refine this scoring system we considered whether POLE variants were 
recurrent in EC within the COSMIC or TCGA databases, as recurrent mutations are 
more likely to be pathogenic (that is causal of tumour ultramutation)[37]. 48/54 (88.9%) 
EC scoring ≥3 points had a recurrent POLE mutation (including hotspot mutations), 
compared to 7/28 (25%) tumours scoring ≤2 points (p≤0.001, χ2 statistics). Restricting 
the analysis to non-hotspot POLE EDM, 7/8 (87.5%) tumours scoring ≥3 points had a 
recurrent mutation versus 5/10 (50%) scoring ≤2 points (p=0.152, Fisher’s exact test). 
Based on these results, “recurrence” was incorporated into the final scoring system 
(Figure 2), which we termed the “POLE pathogenicity score” (POLE-score) (Table 1 
and Figure 1). 
 
To define a cut-off for pathogenicity we applied the POLE-score on hotspot 
POLE-mutant, non-hotspot POLE EDM and control POLE wild-type EC (MSS and MSI-
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H) in the TCGA cohort. 38/41 (92.7%) EC with a hotspot POLE EDM had a POLE-
score of ≥ 5 points (Figure 1). The remaining three tumours, all of which harboured a 
V411L mutation, scored 4 points. In contrast, of the 18 tumours with a non-hotspot 
POLE EDM, seven scored ≥ 4 points (all of which carried mutations recurrent in the 
TCGA or COSMIC EC databases: F367S, L424I, M295R, P436R, M444K, D368Y), five 
scored 3 points (four of which carried recurrent mutations: A465V, L424V, T278M, 
L424I, one with a non-recurrent A428T substitution), and six scored ≤2 points (one of 
which had a recurrent mutation). For comparison, all 321 MSS, POLE wild-type EC 
scored ≤3 points and all 127 MSI-H POLE wild-type EC scored ≤ 2.  
 
Based on these data we used a POLE-score of ≥4 points to define pathogenicity 
of POLE mutations in EC. When applying this cut-off, 48 EC in the TCGA are classified 
as having pathogenic POLE EDM (all 41 cases with hotspot mutations and 7 with non-
hotspot variants); comprising eleven unique mutations, all of which are recurrent in 
TCGA/COSMIC (Table 3). EC with a POLE-score ≤2 were classified as non-pathogenic 
POLE EDM, based on the absence of genomic alterations associated with ultramutated 
phenotype. POLE EDM with a score of 3 (A465V, L424V, T278M, and A428T) were 
classified as of uncertain significance.  
To validate the POLE-score, we noted the contribution of COSMIC signature 10 
in EC with a POLE EDM EC with a POLE-score ≥4 points: signature 10 was present in 
46 EC (95.8%) (mean 0.623, range 0.000–1.000) and completely absent in two EC 
(L424I and V411L). The contribution of signature 10 in EC with one of the five hotspot 
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POLE EDM ranged from 0.978–0.123. Only in one (20.0%) EC with a POLE EDM 
classified as VUS (L424V) and one (16.7%) EC with a POLE EDM classified as non-
pathogenic (D368*) activity of COSMIC signature 10 was identified (mean contribution 
0.106, range 0.00–0.529 and mean 0.002, range 0.000–0.011 respectively). In 
comparison, COSMIC signature 10 was identified in 11 (8.7%) MSI-POLEwt and 96 
(29.9%) MSS-POLEwt EC (mean signature 10 contribution 0.002, range 0.000–0.048, 
and mean 0.017, range 0.000–0.218 respectively). 
 
Relationship between pathogenicity of somatic POLE mutations, microsatellite 
Instability and clinical outcome 
The co-existence of POLE mutations and MMRd/MSI in EC [26,38], and the variation in 
its prevalence by POLE mutation location, raise important questions about which is the 
initial, presumably dominant factor determining tumour phenotype and clinical outcome. 
To further investigate this, we used the POLE-score to stratify TCGA cases into 
predicted pathogenic and non-pathogenic POLE mutations using a score of > 4.  9/49 
(18.4%) EC with a predicted pathogenic POLE mutation (including 4 known hotspot 
mutations) were MSI-H, compared to 26/33 (78.8%) tumours with a predicted non-
pathogenic mutation (p≤0.0001 χ2 statistic). Restricting the analysis to tumours with 
POLE EDM, 9/48 (18.8%) cases with a predicted pathogenic EDM (including hotspot 
mutations) were MSI-H as opposed to 9/11 (81.8%) with a predicted non-pathogenic 
EDM (p≤0.0001 Fisher’s exact test). Interestingly, further stratification suggested 
similar variation between likely pathogenic POLE mutations, as only 2/34 EC with a 
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P286R or V411L mutation were MSI-H, compared to 7/14 EC with one of the other 9 
predicted pathogenic mutations (p=0.0012). Thus, POLE mutations co-existent with 
MSI in EC are more likely to be non-exonuclease, non-pathogenic mutations, though 
this is not universally the case.  
 
To investigate the clinical outcome of POLE exonuclease domain-mutant EC 
with concomitant MMRd, we identified 30 such patients from a pooled analysis of 3,236 
EC (Table 4). 5-year recurrence-free survival (RFS) for this subgroup was 83.2%, with 
5-year Overall Survival (OS) of 80.9% (Figure 3) (corresponding figures for 24 patients 
with stage I disease were 84.2% and 85.4% respectively) (supplementary material, 
Figure S1), seemingly contrasting with the 5-year RFS and OS of 92–100% previously 
reported for POLE exonuclease domain-mutant EC [4,5,7]. To clarify this, we stratified 
patients according to predicted pathogenic versus non-pathogenic EDM using POLE-
score and analysed their clinical outcome. For cases that lacked WES data and which 
POLE EDM had not been previously described in the TCGA, we considered all 
mutations different to the ones present in table 3 (mutations deemed pathogenic using 
the POLE-score) as VUS. This revealed that the 13 cases with one of the 11 mutations 
classified as likely pathogenic by POLE-score (Table 3) had 5 year RFS of 92.3%, 
while the corresponding value for the 14 patients with EDM classified as likely non-
pathogenic/VUS was 76.2% (p= 0.40, log rank test) (Figure 3). While the clinical 
behaviour of tumours with combined MMRd/MSI and POLE EDM may vary based on 
the pathogenicity of the latter, this difference was not statistically significant, possibly 
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owing to insufficient power/small numbers of cases, and it is not possible to determine 
the prognosis of this subgroup with certainty at present. 
 
Estimation of pathogenicity of somatic POLE mutations in the absence of exome 
or genome sequencing  
Somatic mutation profiling in clinical practice is typically performed by targeted panel 
sequencing, rather than WES/WGS approaches at present. To develop a classification 
tool for ECs with somatic non-hotspot POLE mutations that can be implemented using 
such data, we used mutation location, prior data and in silico tools which estimate the 
probability that a mutation is damaging. We first noted that nearly all (>95%) POLE 
mutations outside the exonuclease domain are classified as non-pathogenic by POLE-
score. We next noted that in the case of exonuclease domain mutations reported in 
TCGA, the POLE-score can be used to estimate pathogenicity (Table 3). We finally 
noted that for POLE EDM not present in TCGA, in silico prediction tools could be used 
to estimate pathogenicity.  Further exploration of this revealed that 10/11 POLE EDM 
classified as pathogenic by POLE-score in the TCGA cases were universally predicted 
to be disruptive by six in silico tools, the exception being an L424I substitution predicted 
to be deleterious by five tools but benign by one. However, of five POLE EDM present 
in TCGA but classified as non-pathogenic by POLE-score, one (S461L, POLE-score 2) 
was predicted to be damaging by all six tools, while another variant (E396G, POLE-
score 1) was predicted to be damaging by four tools. Furthermore, of four mutations 
classified as uncertain pathogenicity with POLE-score of 3, three (A465V, L424V, 
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T278M) were considered damaging by all in silico prediction tools while the other 
(A428T) was considered benign by 5/6 prediction tools. Thus, in silico tools appear 
sensitive but not specific for prediction of pathogenic POLE EDM, in the sense of their 
being likely causal for tumour ultramutation.  
 
To define the extent of the problem of ascribing pathogenicity to POLE 
mutations in clinical practice, we identified 296/3840 (7.7%) tumours with a somatic 
POLE mutation from EC cohorts other than TCGA [6,7,9–15,17–22,24,25] (Table 5, 
supplementary material, Table S3). Of 296 non-TCGA POLE-mutant EC reported in the 
literature, 15 had mutations outside the exonuclease domain, and 254 carried 
mutations in the exonuclease domain previously detected in TCGA and classified by 
POLE-scores as pathogenic (249 cases), of uncertain pathogenicity (four cases), or 
non-pathogenic (one case). The remaining 27 cancers with POLE EDM could not be 
classified by POLE-score because their genomic correlates are yet to be determined by 
WES. This represents 9.1% of all reported POLE mutations, or 0.7% of non-TCGA 
molecularly-subtyped EC to date. Of these 27 unique POLE EDM, one was predicted to 
be benign by most in silico tools, while the others were predicted to be damaging by ≥4 
tools (Table 5). The greater negative predictive value than positive predictive value of 
these tools, noted above, suggests that benign predictions should carry more weight, 
and that the former are non-pathogenic mutations, while the latter should be regarded 
as of uncertain pathogenicity. Cases such as these could be prioritised for more 
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comprehensive sequencing, such as WES to provide sufficient data to determine their 
POLE-score.  
 
Recommendations for classification of somatic POLE mutations in clinical 
practice 
Based on the analyses above, we developed a pragmatic tool to classify EC with 
somatic POLE mutations in clinical practice, shown in Table 6 [39,40]. For cases with 
WES/WGS, POLE-score and the presence or absence of MSI/MMRd can be used to 
stratify cases into POLEmut, MMRd, or one of the other two TCGA subgroups 
depending on p53 status (Singh, et al [41]). It is important to note that the presence of a 
POLE mutation alone is insufficient to classify tumours as “POLEmut”, and that 
classification of tumours with combined POLE mutation and MMRd/MSI depends on 
the POLE-score (i.e. genomic correlates) of the POLE mutation. For cases without 
WES/WGS, POLE-score can be used if the POLE mutation has previously been 
reported in TCGA. Where this is not the case, in silico tools can be used to triage 








The development of pragmatic surrogate markers has accelerated the clinical 
implementation of molecular EC classification. The presence of a pathogenic POLE 
EDM is causal for ultramutated EC, a subtype associated with enhanced immune 
response [2,42] and excellent clinical outcome [6,7,13]. De-escalating adjuvant 
treatment in these patients is currently under investigation in the randomised 
PORTEC4a trial. However, interpretation of POLE sequence variants is challenging 
due to lack of standardized criteria, other than for the most common “hotspot” 
mutations for which pathogenicity is reliably established. We aimed to generate tools to 
estimate the pathogenicity of POLE mutations using WES data, and to guide the 
management of cases where comprehensive genomic profiling is not available.   
 
Using cases with recurrent “hotspot” POLE EDM as a truth set, we identified 
their characteristic genomic correlates to generate a “POLE-score”. In addition to 
correctly classifying all cases with POLE hotspot mutations in the TCGA cohort, it 
classified a further six POLE EDM as likely pathogenic.  Four exonuclease domain 
mutations had POLE-score of 3 and were classified as being of uncertain 
pathogenicity, while three cases with POLE mutations outside the exonuclease domain 
had a POLE-score of 3 – all of which carried a plausibly pathogenic POLD1  mutation 
that could explain the mutational spectrum [8]. Intriguingly, a single case with a POLE 
mutation outside the exonuclease domain (R705W) was classified as pathogenic by 
POLE-score. The location of the mutation within the catalytic domain, close to the 
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polymerase active sites, may explain this mutational spectrum, however the clinical 
significance of this is unclear at present. 
 
Because POLE-score relies on WES or WGS to estimate TMB and mutation 
proportions, it is unable to assign pathogenicity in the case of novel POLE mutations 
detected by targeted sequencing, where breadth is typically inadequate to estimate 
these parameters. Although this represents a potential challenge in clinical practice 
where targeted approaches are common, our pooled analysis suggests this situation is 
uncommon – only 0.7% of EC at the time of writing; a figure that will drop over the 
coming years as more WES/WGS data are accrued. We found that pathogenicity of 
such variants is not well reliably predicted by in silico tools, which have low specificity. 
We suggest an approach to these tumours (outlined in Table 6), which may guide the 
use of additional sequencing (e.g. WES) to permit calculation of POLE-score in these 
cases. Although WES remains relatively costly compared to targeted approaches, such 
outlay is modest against that of local or systemic therapy, and thus remains a possible 
approach for cases where a significant treatment decision hangs in the balance.  
 
Our study confirms the complex relationship between POLE mutations and DNA 
mismatch repair deficiency/microsatellite instability. Perhaps most straightforward are 
those with POLE mutations outside the exonuclease domain: these appear to be 
passengers secondary to the hypermutator phenotype and should be classified as 
MMRd. Coexistence of POLE EDM with MSI/MMRd is relatively uncommon, occurring 
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in 3.4% cases in TCGA and 0.9% cases of molecular subtyped tumours in our pooled 
series (this variation probably reflects a combination of targeted sequencing with 
enrichment for pathogenic POLE mutations in the latter cases). This group of tumours 
is heterogeneous. Those with POLE mutations predicted as pathogenic by POLE-score 
and MSI had genomic architecture similar to POLE hotspot-mutant/MSS tumours, 
supporting their classification as POLEmut EC. Those with POLE mutations predicted 
as non-pathogenic by POLE-score and MSI more closely resembled POLE-wild-type 
MSI cases, supporting their classification as MMRd EC. POLE EDM in combination 
with MMR loss cause a distinct mutational signature in EC (COSMIC Signature 14) 
[1,38] – the observation that this is not universal in cases with both defects supports the 
notion that these tumours are a heterogeneous group, where MSI/MMRd could be 
acquired after POLE EDM and vice versa, with differing impacts on prognosis. 
Interestingly, while data were limited, patients with combined pathogenic POLE EDM 
and MSI appeared to have good clinical outcome in our pooled cohort (5-year RFS 
92.3%), though additional cases are required before this can be concluded.  
 
 In conclusion, our work provides guidance in the diagnostic interpretation of 
POLE mutations in endometrial cancer in the presence and absence of WES data. 
Tumours with any of the 11 POLE EDM identified in TCGA and classified as 
pathogenic by POLE-score should be classified as “POLE ultramutated” EC 
independently of MMRd/MSI status. For cases where a POLE EDM not present in 
TCGA is identified, and WES are available, POLE-score can be used for classification. 
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In the absence of WES data, classification should be informed by the results of POLE-
score on mutations reported in TCGA and classified in Table 3. In silico prediction tools 
have limited value but may be able to identify benign changes and triage cases for 
WES/WGS. The guidelines we provide will evolve over time but will allow for almost all 
tumours encountered to be classified into a molecular subtype based on currently 
available information.  
 
Acknowledgements  
This work was supported by the Dutch Cancer Society (KWF-YIG 8232-31648, AL and 
TB), the National Institute for Health Research (NIHR) Oxford Biomedical Research 
Centre (BRC) (DNC) and the BC Cancer Foundation and Michael Smith Foundation for 
Health Research (JM). DNC is funded by an Advanced Clinician Scientist Fellowship 
from Cancer Research UK (C26642/A27963) and was previously funded by a Clinician 
Scientist Fellowship from the Academy of Medical Sciences/Health Foundation. The 
views expressed are those of the author(s) and not necessarily those of the NHS, the 
NIHR or the Department of Health. We would like to thank Tissue bank Bern for 
providing tissues for study purposes. 
 
Author contributions statement  
AL and HB carried out experiments and analysed data. TB, CBG, DNC and MM 
conceived experiments and analysed data. JNM, RN, SK, SYB, JWC, EE and TTR 
This article is protected by copyright. All rights reserved.
 
 
analysed data. All authors were involved in writing the paper and had final approval of 
the submitted and published versions. 
  





1. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. 
Nature. 2013;500(7463):415-21. 
2. van Gool IC, Eggink FA, Freeman-Mills L, et al. POLE Proofreading Mutations Elicit an Antitumor 
Immune Response in Endometrial Cancer. Clin Cancer Res. 2015;21(14):3347-55. 
3. Howitt BE, Shukla SA, Sholl LM, et al. Association of Polymerase e-Mutated and Microsatellite-
Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, 
and Expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319-23. 
4. Stelloo E, Nout RA, Osse EM, et al. Improved Risk Assessment by Integrating Molecular and 
Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC 
Cohorts. Clin Cancer Res. 2016;22(16):4215-24. 
5. Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for 
endometrial cancers. Br J Cancer. 2015;113(2):299-310. 
6. McConechy MK, Talhouk A, Leung S, et al. Endometrial Carcinomas with POLE Exonuclease Domain 
Mutations Have a Favorable Prognosis. Clin Cancer Res. 2016;22(12):2865-73. 
7. Cancer Genome Atlas Research N, Kandoth C, Schultz N, et al. Integrated genomic characterization 
of endometrial carcinoma. Nature. 2013;497(7447):67-73. 
8. Rayner E, van Gool IC, Palles C, et al. A panoply of errors: polymerase proofreading domain 
mutations in cancer. Nat Rev Cancer. 2016;16(2):71-81. 
9. Bellone S, Bignotti E, Lonardi S, et al. Polymerase epsilon (POLE) ultra-mutation in uterine tumors 
correlates with T lymphocyte infiltration and increased resistance to platinum-based 
chemotherapy in vitro. Gynecol Oncol. 2017;144(1):146-52. 
10. Bellone S, Centritto F, Black J, et al. Polymerase epsilon (POLE) ultra-mutated tumors induce robust 
tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 
2015;138(1):11-7. 
11. Billingsley CC, Cohn DE, Mutch DG, et al. Polymerase varepsilon (POLE) mutations in endometrial 
cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer. 2015;121(3):386-
94. 
12. Church DN, Briggs SE, Palles C, et al. DNA polymerase epsilon and delta exonuclease domain 
mutations in endometrial cancer. Hum Mol Genet. 2013;22(14):2820-8. 
13. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in 
endometrial cancer. J Natl Cancer Inst. 2015;107(1):402. 
14. Eggink FA, Van Gool IC, Leary A, et al. Immunological profiling of molecularly classified high-risk 
endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates 
for checkpoint inhibition. Oncoimmunology. 2017;6(2):e1264565. 
15. Espinosa I, Lee CH, D'Angelo E, et al. Undifferentiated and Dedifferentiated Endometrial 
Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis. Am J Surg 
Pathol. 2017;41(8):1121-8. 
16. Hussein YR, Weigelt B, Levine DA, et al. Clinicopathological analysis of endometrial carcinomas 
harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28(4):505-14. 
17. Jansen AM, van Wezel T, van den Akker BE, et al. Combined mismatch repair and POLE/POLD1 
defects explain unresolved suspected Lynch syndrome cancers. Eur J Hum Genet. 2016;24(7):1089-
92. 
This article is protected by copyright. All rights reserved.
 
 
18. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies 
recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat 
Genet. 2012;44(12):1310-5. 
19. Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long 
progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol. 
2014;134(1):15-9. 
20. Wong A, Kuick CH, Wong WL, et al. Mutation spectrum of POLE and POLD1 mutations in South East 
Asian women presenting with grade 3 endometrioid endometrial carcinomas. Gynecol Oncol. 
2016;141(1):113-20. 
21. Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number 
mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013;110(8):2916-21. 
22. Soumerai TE, Donoghue MTA, Bandlamudi C, et al. Clinical Utility of Prospective Molecular 
Characterization in Advanced Endometrial Cancer. Clin Cancer Res. 2018;24(23):5939-47. 
23. Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-
risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836-44. 
24. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based 
clinical classifier for endometrial cancer. Cancer. 2017;123(5):802-13. 
25. Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier 
for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180-8. 
26. Shinbrot E, Henninger EE, Weinhold N, et al. Exonuclease mutations in DNA polymerase epsilon 
reveal replication strand specific mutation patterns and human origins of replication. Genome Res. 
2014;24(11):1740-50. 
27. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis 
colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 
2004;96(4):261-8. 
28. Petljak M, Alexandrov LB. Understanding mutagenesis through delineation of mutational 
signatures in human cancer. Carcinogenesis. 2016;37(6):531-40. 
29. Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic 
signature in urothelial tumors. Nature Genetics. 2016;48:600. 
30. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein 
function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073-81. 
31. Choi Y, Sims GE, Murphy S, et al. Predicting the functional effect of amino acid substitutions and 
indels. PLoS One. 2012;7(10):e46688. 
32. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense 
mutations. Nat Methods. 2010;7(4):248-9. 
33. Mi H, Poudel S, Muruganujan A, et al. PANTHER version 10: expanded protein families and 
functions, and analysis tools. Nucleic Acids Res. 2016;44(D1):D336-42. 
34. Hecht M, Bromberg Y, Rost B. Better prediction of functional effects for sequence variants. BMC 
Genomics. 2015;16 Suppl 8:S1. 
35. Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An Ensemble Method for Predicting the 
Pathogenicity of Rare Missense Variants. Am J Hum Genet. 2016;99(4):877-85. 
36. León-Castillo A, Gilvazquez E, Nout R, et al. Clinicopathological and Molecular Characterisation of 
“Multiple Classifier” Endometrial Carcinomas. J Pathol. 2019; in press  (19-372.R1). 
37. Campbell BB, Light N, Fabrizio D, et al. Comprehensive Analysis of Hypermutation in Human 
Cancer. Cell. 2017. 
This article is protected by copyright. All rights reserved.
 
 
38. Haradhvala NJ, Kim J, Maruvka YE, et al. Distinct mutational signatures characterize concurrent loss 
of polymerase proofreading and mismatch repair. Nat Commun. 2018;9(1):1746. 
39. Valle L, Hernandez-Illan E, Bellido F, et al. New insights into POLE and POLD1 germline mutations in 
familial colorectal cancer and polyposis. Hum Mol Genet. 2014;23(13):3506-12. 
40. Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of 
POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136-
44. 
41. Singh N, Piskorz A, Bosse T, et al. p53 Immunohistochemistry is a an Accurate Surrogate for TP53 
Mutational Analysis in Endometrial Carcinoma Biopsies. J Pathol 2019; in press (19-374.R1). 
42. Talhouk A, Derocher H, Schmidt P, et al. Molecular Subtype Not Immune Response Drives 
Outcomes in Endometrial Carcinoma. Clin Cancer Res. 2019;25(8):2537-48. 
  
This article is protected by copyright. All rights reserved.
 
 
Figure legends  
 
Figure 1. Mutational features of EC with POLE variants in the TCGA. The colour 
scheme for the mutation type is on the right of the histogram. Cases are grouped by 
mutations, with the most frequent POLE mutations in first place. The COSMIC 10 
signature contribution, the points obtained in the POLE pathogenicity score, the 
recurrence of the variant in EC, microsatellite instability (MSI) status and POLE domain 
mutated are colour coded (legend on the right of the histogram). Below are the cases 
without POLE mutations; two rows depict the median plus standard deviation of the 
base change proportions and tumour mutation burden (TMB) of MSI-H and MSS EC 
without a POLE mutation in the TCGA.  
 
Figure 2, POLE genomic alteration score (POLE-score). Diagnostic scoring system 
based on mutation type proportion and TMB of the five hotspot POLE mutations, as 
well as the variant recurrence. 
 
Figure 3. Clinical outcome of MMRd-POLEmut EC. Kaplan–Meier survival curves of 
RFS (A) and OS (B) of MMRd-POLEmut EC. RFS and OS of MMRd-POLEmut EC with 
a pathogenic POLE EDM (mutation present in Table 3) versus all other tumours 
MMRd-POLEmut (C and D). 
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Table 1. POLE variants in TCGA EC.
























P286R 21 c.857C>G 9 1 (4.8) Recurrent Recurrent 0 5–6 Y 0.225–0.978
V411L 13 c.1231G>T/C 13 1 (7.7) Recurrent Recurrent 1 4–6 Y 0.000–0.751
S297F 3 c.890C>T 9 2 (66.7) Recurrent Recurrent 0 5–6 Y 0.123–0.611
S459F 2 c.1376C>T 14 0 (0) Recurrent Recurrent 1 5–6 Y 0.940–0.955
A456P 2 c.1366G>C 14 0 (0) Recurrent Recurrent 0 5–6 Y 0.277–0.837
F367S 2 c.1100T>C 11 2 (100) Recurrent Recurrent 0 6 Y 0.095–0.100
L424I 2 c.1270C>A 13 2 (100) Recurrent Recurrent 1 5 or 3 Y 0.000–0.000
M295R 1 c.884T>G 9 1 (100) Recurrent Recurrent 0 6 Y 0.785
P436R 1 c.1307C>G 13 0 (0) Recurrent Recurrent 0 6 Y 0.230
M444K 1 c.1331T>A 13 0 (0) Recurrent Recurrent 0 5 Y 1.000
R705W 1 c.2113C>T 19 0 (0) Novel Novel 1 5 N 0.821
D368Y 1 c.1102G>T 11 1 (100) Novel Recurrent 0 4 Y 0.042
M1754V 1 c.5260A>G 39 1 (100) Novel Novel 5 3 N 0.000
K1070N 1 c.3210G>T 26 1 (100) Novel Novel 1 3 N 0.000
L424V 1 c.1270C>G 13 0 (0) Recurrent Recurrent 0 3 Y 0.529
A428T 1 c.1282G>A 13 0 (0) Novel Novel 5 3 Y 0.000
R742H 1 c.2225G>A 20 1 (100) Novel Recurrent 1 3 N 0.018
Q1335* 1 c.4003C>T 30 1 (100) Novel Novel NA 3 N 0.000
T278M 1 c.833C>T 9 1 (100) Recurrent Recurrent 0 3 Y 0.000
A465V 1 c.1394C>T 14 1 (100) Recurrent Recurrent 0 3 Y 0.000
S461L 1 c.1382C>T 14 1 (100) Novel Novel 0 2 Y 0.000
R114* 1 c.340C>T 5 1 (100) Recurrent Recurrent NA 2 N 0.000
F990C 1 c.2969T>G 25 0 (0) Novel Novel 0 1 N 0.000
W1824C 1 c.5472G>T 40 0 (0) Novel Novel 0 1 N 0.000
E396G 1 c.1187A>G 12 1 (100) Recurrent Recurrent 2 1 Y 0.000
A1140T 1 c.3418G>A 28 1 (100) Novel Recurrent 5 1 N 0.000
Y1889C 1 c.5666A>G 41 1 (100) Novel Novel 0 1 N 0.000
A781S 1 c.2341G>T 21 1 (100) Novel Novel 6 1 N 0.000
R34C 1 c.100C>T 2 0 (0) Recurrent Recurrent 1 1 N 0.000
E1461V 1 c.4382A>T 34 1 (100) Novel Novel 5 1 N 0.000
R976S 1 c.2926C>A 25 0 (0) Novel Novel 1 0 N 0.000
V2025M 1 c.6073G>A 44 1 (100) Novel Novel 6 0 N 0.000
A566T 1 c.1696G>A 16 1 (100) Novel Novel 2 0 N 0.000
R1386Q 1 c.4157G>A 33 0 (0) Novel Novel 2 0 N 0.022
D368* 1 c.1101dupT 11 1 (100) Novel Novel NA 0 Y 0.011
R1321K 1 c.3962G>A 31 1 (100) Novel Novel 5 0 N 0.000
Q1049H 1 c.3147G>T 26 1 (100) Novel Novel 2 0 N 0.000
R764M 1 c.2291G>T 20 1 (100) Novel Novel 0 0 N 0.000
E1698D 1 c.5094G>T 38 1 (100) Novel Novel 1 0 N 0.000
A1010T 1 c.3028G>A 25 1 (100) Novel Novel 1 0 N 0.000
C402R 1 c.1204T>C 12 1 (100) Novel Novel 3 0 Y 0.000
T906I 1 c.2717C>T 24 1 (100) Novel Novel 0 0 N 0.000
Q352H 1 c.1056G>T 11 1 (100) Novel Novel 4 0 Y 0.000
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Table 2. Tumour mutation burden and SNV/indel by POLE mutation location and tumour MSI status in TCGA endometrial cancers.
EC with hotspot POLE mutations EC with non-hotspot POLE EDM EC with POLE non-exonuclease domain mutations
MSI-POLEwt EC MSS-POLEwt EC
Total MSS MSI Total MSS MSI Total MSS MSI 
n=41 n=37 n=4 n=18 4,0 n=14 n=23 n=6 n=17 n=127 n=321
Tumour Mutational Burden




550.1) 164.4 (1.1–530.4) 27.3 (1.1–262.9)
207.1 (26.9–
530.4) 42.8 (1.7–452.9) 4 (1.7–236.2) 48.5 (17.4–452.9) 21.5 (0.0–150.5) 2.1 (0.3–59.0)
≥100mut/Mb (%) 33 (80.5) 29 (78.4) 4 (100) 10 (55.6) 1 (25) 9 (64.3) 7 (30.4) 1 (16.7) 6 (35.3) 1 (0.8) 0 (0)
Percentage of C:G>A:T 
Median (range) 32.5 (4.3–45.2) 33.0 (16.0–45.2) 20.0 (4.3–32.5) 20.2 (6.9–46.9) 27.0 (21.4–46.7) 10.8 (6.9–46.9) 10.8 (3.9–32.3) 16.9 (5.0–32.3) 9.9 (3.9–28.1) 9.1 (0.0–23.2) 13.5 (2.8–27.6)
Proportion≥20% (%) 37 (90.2) 35 (94.6) 2 (50) 9 (50) 4 (100) 5 (35.7) 4 (17.4) 2 (33.3) 2 (11.8) 1 (0.8) 25 (7.8)
Percentage of C:G>G:C
Median (range) 0.3 (0.2–0.6) 0.3 (0.2–0.6) 0.3 (0.2–0.6) 0.5 (0.2–9.5) 0.7 (0.3–9.5) 0.5 (0.2–2.0) 1.0 (0.2–26.1) 5.0 (0.3–26.1) 0.9 (0.2–2.0) 1.5 (0.0–8.8) 8.9 (0.0–47.7)
Proportion<0.6% (%) 37 (90.2) 34 (91.9) 3 (75) 11 (61.1) 2 (50) 9 (64.3) 6 (26.1) 1 (16.7) 5 (29.4) 5 (3.9) 2 (0.6)
Percentage of C:G>T:A
Median (range) 43.6 (26.2–77.4) 40.7 (26.2–63.1) 58.3 (50.8–77.4) 52.1 (35.2–77.7) 50.9 (35.2–55.3) 52.1 (40.9–77.7) 45.9 (20.5–77.7) 47.2 (21.0–70.2) 44.6 (20.5–77.7) 46.0 (0.0–79.9) 47.9 (4.7–85.5)
Percentage of T:A>A:T
Median (range) 1.1 (0.5–1.7) 1.1 (0.5–1.6) 1.4 (0.8–1.7) 1.5 (0.7–4.8) 1.3 (1.1–4.8) 1.5 (0.7–3.4) 2.4 (1.1–6.8) 4.3 (1.1–6.8) 2.3 (1.1–5.9) 1.9 (0.0–8.2) 4.5 (0.0–12.4)
Percentage of T:A>C:G
Median (range) 8.9 (5.2–29.5) 8.4 (5.2–29.5) 10.7 (7.4–11.8) 8.9 (3.1–15.1) 7.9 (4.6–12.1) 9.5 (3.1–15.1) 11.8 (9.2–52.2) 10.7 (9.2–11.8) 12.1 (9.5–52.2) 11.7 (2.4–100.0) 9.3 (1.3–30.3)
Percentage of T:A>G:C
Median (range) 12.8 (2.9–21.7) 13.0 (4.0–21.7) 5.1 (2.9–7.0) 2.3 (0.6–11.7) 6.0 (3.2–11.7) 1.6 (0.6–5.8) 1.6 (0.6–20.5) 1.8 (1.2–20.5) 1.6 (0.6–4.5) 1.4 (0.0–8.0) 3.9 (0.0–13.1)
Proportion≥4% (%) 38 (92.7) 36 (97.3) 2 (50) 6 (33.3) 3 (75) 3 (21.4) 3 (13.0) 2 (33.3) 1 (5.9) 6 (4.7) 154 (48.0)
Percentage of small indels
Median (range) 0.5 (0.2–6.0) 0.5 (0.2–6.0) 2.8 (1.8–4.0) 5.2 (0.4–35.5) 1.5 (0.4–3.2) 6.7 (0.9–35.5) 9.5 (0.4–35.1) 8.9 (0.4–9.7) 14.5 (1.9–35.1) 24.8 (0.0–40.2) 7.4 (0.0–80.9)
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Table 3. Pathogenic POLE EDM based on POLE-score.
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Pathogenic mutation 14 (46.7)
Non-pathogenic mutation/variant 
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A426V 1 (2.4) c.1277C>T 13 Unknown Recurrent Recurrent 1
A456G 1 (2.4) c.1367C>G 14 Unknown Novel Novel 1
A456V 1 (2.4) c.1367C>T 14 0 (0) Novel Recurrent 0
D275V 1 (2.4) c.824A>T 9 Unknown Novel Novel 0
D287E 2 (4.9) c.861T>A/G 9 1 (50) Novel Novel 1
D462E 1 (2.4) c.1386T>A/G 14 0 (0) Novel Novel 1
F367C 1 (2.4) c.1100T>G 11 0 (0) Novel Novel 0
F367L 1 (2.4) c.1101T>A/G 11 1 (100) Novel Novel 0
F367V 1 (2.4) c.1099T>G 11 0 (0) Novel Novel 0
G364V 1 (2.4) c.1091G>T 11 1 (100) Novel Novel 0
G388S 1 (2.4) c.1162G>A 12 0 (0) Novel Novel 0
H342R 1 (2.4) c.1025A>G 11 Unknown Novel Novel 5
L283F 1 (2.4) c.847C>T 9 1 (100) Novel Novel 1
L424P 1 (2.4) c.1271T>C 13 0 (0) Novel Novel 0
M299I 1 (2.4) c.897G>A/C/T 9 0 (0) Novel Novel 0
M405I 1 (2.4) c.1215G>A/C/T 12 0 (0) Novel Novel 2
P286L 1 (2.4) c.857C>T 9 1 (100) Novel Recurrent 0
P286S 1 (2.4) c.856C>T 9 0 (0) Novel Recurrent 0
P436S 2 (4.9) c.1306C>T 13 1 (50) Novel Novel 0
P441L 1 (2.4) c.1322C>T 13 0 (0) Novel Recurrent 1
R375Q 1 (2.4) c.1124G>A 12 0 (0) Novel Novel 1
S297Y 1 (2.4) c.889T>G 9 0 (0) Novel Recurrent 0
T323A 1 (2.4) c.967A>G 10 1 (100) Novel Novel 1
T457M 1 (2.4) c.1370C>T 14 0 (0) Novel Recurrent 2
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Table 6. Recommendations for the interpretation of somatic POLE mutations in EC. 
Recommendations to classify EC with POLE mutations with (A) POLE-score 
available, or (B) POLE-score absent.
A
POLE mutation Predicted pathogenicity MSI/MMR status Treatment recommendation
Exonuclease domain mutation Pathogenic MSS/MMRp POLEmut EC
POLE-score ≥4 Pathogenic MSI/MMRd POLEmut EC1
Exonuclease domain mutation Non-pathogenic MSS/MMRp POLEwt EC
POLE-score <4 Non-pathogenic MSI/MMRd MMRd EC
– MSS/MMRp NSMP/p53abn EC2
Non-exonuclease domain mutation
– MSI/MMRd MMRd EC
If tumours-only sequencing is performed, detection of L424V variant should prompt consideration of germline testing [37, 38]
B
POLE mutation Predicted pathogenicity MSI/MMR status Treatment recommendation
VUS MSS/MMRp WES or NSMP/p53abn EC2,3Exonuclease domain mutation predicted 
to be pathogenic by ≥4 in silico 
prediction tools VUS MSI/MMRd WES or MMRd EC3
Non-pathogenic MSS/MMRp NSMP/p53abn EC2Exonuclease domain mutation predicted 
to be NON-pathogenic by >1 in silico 
prediction tool Non-pathogenic MSI/MMRd MMRd EC
– MSS/MMRp NSMP/p53abn EC2
Non-exonuclease domain mutation
– MSI/MMRd MMRd EC
If tumours-only sequencing is performed, detection of L424V variant should prompt consideration of germline testing [39, 40]
1 Treat as POLEmut EC (based on genomic alteration) independently of MMR status (insufficient data to suggest otherwise)
2 p53-IHC should be performed to exclude a p53abn EC
3 Treat conservatively i.e. as MMRd/NSMP or send for WES






















This article is protected by copyright. All rights reserved.
 





















This article is protected by copyright. All rights reserved.
